Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$0.75
EPS est.
$0.71
EPS surprise
+5.63%
1-day move
+0.57%
Pfizer's earnings report shows a positive surprise in EPS, which likely contributed to the stock's modest increase of 0.57%. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.75 | $0.72 | +5.63% |
| Revenue | N/A | $13.8B | N/A |
No transcript is on record for the earnings call, so analysis is based solely on numerical results.
Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing medicines and vaccines. With a market cap of $150 billion, it plays a crucial role in the health care sector, especially in the wake of the COVID-19 pandemic and ongoing health challenges.
Last quarter
In Q4 2025, Pfizer reported an EPS of $0.66, exceeding expectations by 16.81%. However, the stock fell 3.34% the following day, indicating market caution despite the earnings beat.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+30.82%
Avg 1-day reaction
+0.38%
Analysts expect Pfizer to report solid earnings, with a consensus EPS of $0.72 and revenue of $13.8 billion. The market is closely watching how the company navigates post-COVID dynamics.
Bull case
If Pfizer exceeds EPS expectations, it could signal strong demand for its products and a recovery in its core business, potentially boosting investor confidence.
Bear case
Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and market position.
Key metrics to watch
EPS
$0.72Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$13.8BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Pfizer's EPS exceed the consensus estimate of $0.72?
A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence.
Q2
What guidance will management provide regarding future revenue growth?
Future revenue guidance is crucial for assessing the company's growth trajectory and market outlook.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may underestimate the impact of new product launches and ongoing demand for vaccines, which could drive stronger revenue than expected.
Supporting evidence
Pfizer has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.
The options market is pricing a 4.2% move, suggesting expectations of volatility that may not align with actual performance.
Key risk
If new product sales significantly exceed expectations, it could challenge the current consensus view.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it reflects Pfizer's ability to sustain growth post-COVID and adapt to changing market conditions.
Bull confirmed if
An EPS of $0.75 or higher would confirm strong demand and positive market sentiment.
Bear confirmed if
An EPS below $0.68 would raise concerns about the company's growth and market position.
What the market is pricing for the move.
Implied Move
±4.2%
Historical Avg
±2.2%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±4.5% while PFE has averaged ±2.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
21.0%
Smart-money positioning from the most recent 13F filings.
Institutional
69.16%
of float
Insider
0.10%
of float
Holders
3,618
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
529,670,433 sh · $14.8B
9.29%
6.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Pfizer beats expectations, history suggests the stock could rise by around 1.15%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
If Pfizer misses earnings expectations, history suggests a potential decline of about 3.01%, raising concerns about its growth.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
Senate only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
372,149,852 sh · $10.4B
6.53%
0.7%
State Street Corporation
307,090,897 sh · $8.6B
5.39%
1.8%
Geode Capital Management, LLC
135,275,782 sh · $3.8B
2.37%
1.3%
Vanguard Portfolio Management LLC
119,235,030 sh · $3.3B
2.09%
2.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jun 8, 2026 · disclosed Jul 16, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.